Rhopressa

(Netarsudil)

ApprovedSmall molecule

FFalcon

Rhopressa is one of 48 small molecule programs targeting Proliferative Vitreoretinopathy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Proliferative VitreoretinopathyRecruiting

GlaucomaUnknown status

Proliferative VitreoretinopathyPhase 2

Recruiting

GlaucomaApproved

Unknown status

Competition

Competitive Landscape

54 competitors in Glaucoma

#DrugCompanyPhaseTrials

Alphagan

Novartis

Approved

3 2

Zolymbus

AbbVie

Approved

3 3

Travatan

Novartis

Approved

3 4

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

10 5

Crestor

AstraZeneca

Approved

1 6

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

9 7

Diamox

Teva

Approved

1 8

Neoral

Isopto Carpine

1 10

Tobrex

VViatris Specialty LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Proliferative Vitreoretinopathy

NCT06033703

Clinical

Trials by Indication[1]

Corneal Edema2 trials

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Completed·PPrice Vision Group·Phase 2/3·NCT04051463·29 enrolled

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

Completed·AAerie Pharmaceuticals·Phase 2·NCT04498169·40 enrolled

Adult1 trial

A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

Completed·AAerie Pharmaceuticals·Phase 1·NCT02406287·10 enrolled

Proliferative Vitreoretinopathy1 trial

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

Recruiting·MMassachusetts Eye and Ear Infirmary·Phase 1/2·NCT06033703·48 enrolled

Glaucoma1 trial

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

Unknown status·—·Phase 4·NCT04981886·115 enrolled

Trial1 trial

Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

Terminated·PPrice Vision Group·Phase 2/3·NCT03971357·19 enrolled

2 more indications

Intraocular Pressure1 trial

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

Completed·CCornea Research Foundation of America·Phase 3·NCT03248037·120 enrolled

Unspecified3 trials

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

Unknown status·UUniversity of the Incarnate Word·Phase 1·NCT04234932·10 enrolled

Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

Completed·MMassachusetts Eye and Ear Infirmary·Phase 1·NCT04752020·25 enrolled

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Completed·WWestlake Eye Specialists·Phase 4·NCT06449352·100 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 18, 2017

RHOPRESSA

NDA NDA208254

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Netarsudil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Netarsudil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Netarsudil. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA208254). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Rhopressa. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Falcon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFalcon

Patent Landscape[5]

Patent Cliff

Jan 27, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8450344Jul 11, 2026

9096569Jul 11, 2026

10882840Jul 11, 2026

10654844Jan 27, 2030

8394826Nov 10, 2030

1 more patents

9415043Mar 14, 2034

Rhopressa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Corneal Edema2 trials

Adult1 trial

Proliferative Vitreoretinopathy1 trial

Glaucoma1 trial

Trial1 trial

Intraocular Pressure1 trial

Unspecified3 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News